Brokers Set Expectations for NAMS Q3 Earnings

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) – Analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for shares of NewAmsterdam Pharma in a research report issued on Monday, October 20th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.31) per share for the quarter. HC Wainwright has a “Buy” rating and a $52.00 price target on the stock. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for NewAmsterdam Pharma’s Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.33) EPS, FY2026 earnings at ($1.35) EPS, FY2027 earnings at $2.24 EPS, FY2028 earnings at $3.61 EPS and FY2029 earnings at $6.74 EPS.

Other research analysts have also issued reports about the company. Citigroup increased their price objective on NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a “buy” rating in a research report on Friday. The Goldman Sachs Group began coverage on NewAmsterdam Pharma in a research report on Thursday, July 17th. They issued a “neutral” rating and a $27.00 price target on the stock. Royal Bank Of Canada raised their price target on NewAmsterdam Pharma from $38.00 to $39.00 and gave the stock an “outperform” rating in a research report on Thursday, August 7th. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, July 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Wednesday, October 8th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, NewAmsterdam Pharma has a consensus rating of “Moderate Buy” and a consensus price target of $43.20.

NewAmsterdam Pharma Stock Performance

Shares of NAMS opened at $36.48 on Wednesday. The firm has a market capitalization of $4.11 billion, a price-to-earnings ratio of -22.52 and a beta of 0.02. The business’s fifty day moving average price is $28.32 and its two-hundred day moving average price is $22.52. NewAmsterdam Pharma has a 52 week low of $14.06 and a 52 week high of $41.47.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.37. The business had revenue of $19.15 million for the quarter, compared to analyst estimates of $1.44 million. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%.

Hedge Funds Weigh In On NewAmsterdam Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Frazier Life Sciences Management L.P. grew its holdings in NewAmsterdam Pharma by 3.0% during the second quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company’s stock worth $300,754,000 after purchasing an additional 490,656 shares during the period. RA Capital Management L.P. grew its holdings in NewAmsterdam Pharma by 14.6% during the first quarter. RA Capital Management L.P. now owns 10,138,938 shares of the company’s stock worth $207,544,000 after purchasing an additional 1,293,938 shares during the period. Wellington Management Group LLP grew its holdings in NewAmsterdam Pharma by 53.0% during the first quarter. Wellington Management Group LLP now owns 3,541,975 shares of the company’s stock worth $72,504,000 after purchasing an additional 1,226,852 shares during the period. Adage Capital Partners GP L.L.C. grew its holdings in NewAmsterdam Pharma by 54.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after purchasing an additional 1,062,359 shares during the period. Finally, Woodline Partners LP grew its holdings in NewAmsterdam Pharma by 0.5% during the first quarter. Woodline Partners LP now owns 2,442,397 shares of the company’s stock worth $49,996,000 after purchasing an additional 11,615 shares during the period. Institutional investors own 89.89% of the company’s stock.

Insider Buying and Selling

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $25.83, for a total value of $3,874,500.00. Following the sale, the chief accounting officer owned 15,000 shares of the company’s stock, valued at $387,450. This trade represents a 90.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director James N. Topper purchased 1,260 shares of NewAmsterdam Pharma stock in a transaction that occurred on Monday, September 8th. The shares were bought at an average cost of $24.99 per share, with a total value of $31,487.40. Following the completion of the transaction, the director directly owned 3,027,864 shares of the company’s stock, valued at approximately $75,666,321.36. The trade was a 0.04% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 2,391 shares of company stock valued at $58,424 and have sold 226,342 shares valued at $5,748,019. 20.84% of the stock is currently owned by company insiders.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.